Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
An analysis conducted in Taiwan analyzed health outcomes over more than a decade.
Researchers compared direct-acting-antiviral treatment outcomes between those with and without a history of liver cancer.
Researchers analyzed a cohort of South Koreans taking Viread (tenofovir disoproxil fumarate) or Baraclude (entecavir) for hepatitis B.
These rates are driven in large part by hepatitis B and C.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.